Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)

Inclusion Criteria: * Documented chronic (at least 6 months) HCV GT 1 infection (with no evidence of mixed genotypes or genotype that cannot be assigned a type) * Evidence or no evidence of liver cirrhosis based on one of the following: * Liver biopsy performed within 24 months of Day 1 (if participant is cirrhotic then there is no time restriction on biopsy) * Fibroscan performed within 12 months of Day 1 of this study * Fibrosure™ (Fibrotest™) plus aspartate aminotransferase to platelet Ratio Index \[APRI\] obtained during the screening period) * Has HCV status that is one of the following: * Treatment naïve * Prior interferon or pegylated interferon with or without ribavarin failures (null responder, partial responder, or relapser) * Intolerant to prior interferon or pegylated intereferon with or without ribavarin regimen * Chronic kidney disease (defined as glomerular filtration rate \[eGFR\] \<=29) non-dialysis dependent or on hemodialysis for at least 3 months, including individuals awaiting kidney transplant and those with failed kidney transplants but no longer on immunosuppressant therapy) * Female participant of reproductive potential must agree to remain abstinent or use (or have their partner use) 2 acceptable methods of contraception from at least 2 weeks prior to Day 1 through 14 days after the last dose of study drugs, or longer if dictated by local regulations Exclusion Criteria: * Evidence of decompensated liver disease * On peritoneal dialysis for management of kidney disease * Co-infection with hepatitis B virus or human immunodeficiency virus (HIV) * History of malignancy \<=5 years prior to signing informed consent * Clinical diagnosis of substance abuse * Pregnant, breast-feeding, expecting to conceive or donate eggs, or donate sperm from Day 1 through 14 days after the last study dose, or longer if dictated by local regulations * Organ transplant (including hematopoietic stem cell transplant) other than kidney, cornea, and hair * Conditions requiring, or likely to require, chronic systemic administration of corticosteroids during the course of the trial * Uncontrolled or poorly controlled hypertension * Significant cardiovascular disorder (e.g. myocardial infarction or unstable angina) or cardiovascular procedure within 3 months prior to signing informed consent * New or worsening signs or symptoms of congestive heart failure within 3 months of signing informed consent * Severe active peripheral vascular disease * Recent (within 3 months prior to signing informed consent) episode or recurrence of stroke, transient ischemic attack (TIA) or neurological disorder, including but not limited to seizures * Evidence or history of chronic hepatitis not caused by HCV